Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients
mSystems · 2026
DOI: 10.1128/msystems.00774-25 ↗Kurz gefasst
Klinische Studie in der Zeitschrift mSystems, 2026. Verfasst von Xinjun Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, Ch…. Hauptthemen laut MEDLINE: Infliximab, Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Metabolome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Fecal microbiota transplantation (FMT) is an emerging therapy for inflammatory bowel disease (IBD), yet its efficacy in patients refractory to conventional treatments and its underlying mechanisms require further elucidation. We studied 37 IBD patients (15 ulcerative colitis [UC], 22 Crohn’s disease [CD]) refractory to conventional therapies and 16 healthy donors. FMT monotherapy from a single donor induced week-4 clinical response in 12 UC and 9 biologic-naïve CD patients, with all responders sustaining remission and most achieving endoscopic remission by week 14. Integrated multi-omics revealed FMT restored microbial diversity and profoundly reorganized host-microbiota-metabolite networks. In nine refractory CD patients (7 infliximab [IFX] non-responders, 2 FMT non-responders), IFX-FMT combination led to week-4 response in 6 patients, all of whom attained clinical and endoscopic remission by week 14, with more complete microbial-metabolic restoration than monotherapy. Our findings establish that FMT induces remission in refractory IBD via ecosystem network rewiring, and that IFX-FMT exhibits additive effects, supporting further trials of microbiome-directed adjunctive strategies. IMPORTANCE This study provides mechanistic and clinical insights into the therapeutic effects of fecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD), particularly when combined with the anti-tumor necrosis factor (anti-TNF) biologic infliximab (IFX). While both FMT and IFX achieve response in approximately 60% of IBD patients, their combined influence on the gut microbial and metabolic landscape in refractory disease has been poorly understood. Here, we demonstrate that FMT monotherapy restores gut microbial diversity and reconfigures host-microbiota-metabolite networks, correlating with clinical and endoscopic remission in patients refractory to conventional treatments. Furthermore, in Crohn's disease patients unresponsive to either therapy alone, combined IFX-FMT induced more complete microbial and metabolic normalization and achieved remission where monotherapy had failed. These findings reveal ecosystem-level network rewiring as a central mechanism of FMT efficacy and establish the additive potential of combining microbiome-targeted and immunomodulatory therapies. This work supports the development of microbiome-informed adjunctive strategies for severe or refractory IBD, highlighting an actionable path toward personalized, mechanism-based treatment regimens. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT07149441 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
- Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
- Shanghai Gastrointestinal Microecology Research Center, Shanghai, China.
- Shanghai Institution of Gut Microbiota Research and Engineering Development, Shanghai, China.
- Clinical Research Center for Digestive Diseases, Tongji University School of Medicine, Shanghai, China.
- Shanghai Zhangjiang Institute of Medical Innovation, Shanghai, China.
ORCID-Profile: Xinjun Wang, Le Wang, Qiyi Chen, Di Zhao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Wu, W., Yang, B., Liu, Y., Xu, Y., Wang, L., Lv, X., Gao, J., Lu, M., Yu, A., Li, N., Chen, Q., Lu, L., & Zhao, D. (2026). Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients. mSystems. https://doi.org/10.1128/msystems.00774-25
Vancouver
Wang X, Wu W, Yang B, Liu Y, Xu Y, Wang L, et al. Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients. mSystems. 2026. doi:10.1128/msystems.00774-25
BibTeX
@article{Wang2026,
author = {Wang, Xinjun and Wu, Weijun and Yang, Bo and Liu, Yunkun and Xu, Yue and Wang, Le and Lv, Xiaoqiong and Gao, Junhui and Lu, Man and Yu, Anqi and Li, Ning and Chen, Qiyi and Lu, Liesheng and Zhao, Di},
title = {Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients},
journal = {mSystems},
year = {2026},
doi = {10.1128/msystems.00774-25}
}
EUVIMED